BALVERSA (erdafitinib) Patient Assistance Program
A targeted bladder-cancer therapy shouldn’t be priced out of reach. The Johnson & Johnson Patient Assistance Program provides Balversa free of charge to eligible patients — including many on Medicare — and we manage the entire enrollment for a flat $69.95 per month.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey.
- Annual Re-certification And Refills Management
- FGFR-Testing Documentation Support — The Prerequisite Insurers Check First
HIPAA Compliant
BBB Accredited
Secure Website
Key Takeaways:
- Balversa (Erdafitinib) Is A Targeted Oral Therapy For Locally Advanced Or Metastatic Urothelial (Bladder) Cancer With Susceptible FGFR3 Genetic Alterations — A Once-Daily Pill Prescribed Only After Tumor Testing Confirms The FGFR Target.
- Cash Prices Run Roughly $28,000–$32,000 Per Month At The Standard 8 mg Daily Dose — Over $340,000 Per Year. No Generic Can Launch For Years: Only A Tentative Generic Approval Exists (February 2026), Blocked By Patents Running To 2036.
- The Johnson & Johnson Patient Assistance Program Provides Balversa Free For Up To A Year To Patients With Household Income At Or Below 400% Of The Federal Poverty Level — Including Medicare Part D Patients Who Can’t Afford Their Medicine.
- Commercially Insured Patients Pay Just $5 Per Fill Through The J&J withMe Savings Program. Medicare Patients Get The $2,100 Part D Cap (2026) As A Hard Ceiling — Which For A $340,000 Drug Is The Single Most Valuable Protection In This Price Class.
What Is Balversa Prescription Assistance Program?
The Balversa Patient Assistance Program is run by the Johnson & Johnson Patient Assistance Program with its foundation partner, and provides Balversa free of charge for up to a year to qualifying patients: household income at or below 400% of the Federal Poverty Level (roughly $62,600 for one person in 2026), uninsured, underinsured, or on Medicare Part D and unable to afford the medicine (patients at or below 150% FPL first document Extra Help ineligibility). Applying directly (Balversa cost support: 866-378-1910; J&J PAP: 833-742-0791) is always free. Balversa adds a prerequisite most drugs don’t have: it’s prescribed only for tumors with confirmed FGFR3 alterations, so the genetic-testing documentation must be complete before any insurer or program approves — and incomplete FGFR paperwork is the most common avoidable delay in starting treatment. For a flat $69.95 per month, our Patient Advocates coordinate the testing documentation, the application, and every renewal with your oncology team, so a $28,000-a-month prescription never waits on a fax.
Pharmacy Price Comparison
- Without assistance, Balversa costs roughly $19,000–$23,000/month. A Patient Assistance Program is the meaningful path forward — if you qualify:
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Walgreens | ~$22,000 | Save ~$21,930/mo |
| CVS Pharmacy | ~$23,000 | Save ~$22,930/mo |
| Walmart | ~$19,500 | Save ~$19,430/mo |
| Costco | ~$19,200 | Save ~$19,130/mo |
| Specialty Pharmacy | ~$20,000 | Save ~$19,930/mo |
*Just a heads-up — retail prices are estimates based on public data and vary by pharmacy. AffordMyPrescriptions Advocacy Service bypasses this by using drug manufacturer programs to secure your medication directly at no cost or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Balversa Prescription Program?
The J&J Patient Assistance Program is free to apply for and provides Balversa at no drug cost if approved. Our $69.95/month service covers full advocacy — the FGFR documentation, the application, the renewals, and coordination with your cancer center’s financial team.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
We Advocate
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Receive Medication
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Balversa:
Limitations of Coupons
- Prices fluctuate — savings aren’t guaranteed month-to-month
- Copay accumulators may prevent savings from counting toward deductible
- Coupon cards expire and require constant renewal
- Still $19,000–$23,000 per month even with the best discount
- Can’t be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
- Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
- Medication supplied directly through the assistance program
- We manage all paperwork, refills, and annual renewals
- If denied, we explore alternative savings on your behalf
DO YOU QUALIFY?
The Johnson & Johnson Patient Assistance Program publishes clear eligibility rules for free Balversa. You will generally qualify if all of the following are true — and if your situation doesn’t fit neatly, contact AffordMyPrescriptions so we can review your case and determine if you qualify for Balversa assistance:
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Balversa Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or On Medicare Part D And Unable To Afford The Medicine (≤150% FPL Requires Extra Help Ineligibility First)
- Your Household Income Is At Or Below 400% Of The Federal Poverty Level (About $62,600 For One Person)
Not sure if you qualify? Our pre-qualification check is completely free. If we can’t help, you won’t be charged.
Understanding Balversa:
Balversa (erdafitinib) is a fibroblast growth factor receptor (FGFR) kinase inhibitor — a precision therapy for bladder cancers whose growth is driven by specific FGFR3 genetic alterations.
How Balversa Works:
In roughly one in five advanced urothelial cancers, mutations or fusions in the FGFR3 gene leave a growth-signal switch jammed on. Erdafitinib binds the FGFR kinases and shuts that signal down — which is why it works only in tested, FGFR-altered tumors, and why the FDA approval requires a companion diagnostic to confirm the target before treatment. It’s used after platinum chemotherapy and typically after immunotherapy, in a setting where options are few.
Form and Use:
Once-daily oral tablets, started at 8 mg and adjusted based on blood phosphate levels at day 14 and tolerability — an unusual built-in dose-titration step that means your strength (and its price) may change in the first month, which we account for in program paperwork. Treatment continues until progression or unacceptable toxicity.
Generic Availability:
None, and none soon: Natco received only a tentative FDA approval in February 2026, with launch blocked by patents extending to 2036. For the foreseeable future, Balversa’s affordability levers are the withMe program, the J&J PAP, the Part D cap, and oncology foundation grants when funds are open.
Warnings:
Balversa’s signature toxicity is ocular: central serous retinopathy and other eye disorders — regular ophthalmic exams and prompt reporting of any vision change are mandatory. It raises blood phosphate (managed by dose and diet), and causes mouth sores, nail changes, dry skin, and diarrhea frequently enough that supportive care should be planned, not improvised. It can harm a fetus — effective contraception is required during and after treatment.
FAQ (Frequently Asked Questions)
How Much Does Balversa Cost Without Insurance?
Roughly $28,000–$32,000 per month at the standard dose — over $340,000 per year. Patients at or below 400% of the Federal Poverty Level can receive it free through the J&J Patient Assistance Program; our $69.95 monthly fee covers full advocacy and enrollment management.
Does Medicare Cover Balversa?
Yes — as an oral oncology drug under Part D, where the $2,100 annual out-of-pocket cap (2026) is a hard ceiling; the Medicare Prescription Payment Plan can spread that across the year. Income-eligible Part D patients can route through the J&J PAP instead and pay nothing. We check both.
What Is FGFR Testing And Why Does It Matter For Coverage?
Balversa only works against tumors with susceptible FGFR3 alterations, so a positive test is both a clinical requirement and the document every insurer demands at prior authorization. Missing or mislabeled FGFR paperwork is the top cause of avoidable delays — we make sure it’s in the file before anything is submitted.
Can I Use The $5 withMe Program With Medicare?
No — it’s commercial-insurance only. Medicare patients rely on the Part D cap, the payment plan, Extra Help if income-qualified, or the PAP.
How Long Does PAP Approval Last?
Up to one year, with annual re-enrollment. We track the renewal and re-file before coverage lapses — in active cancer treatment, we treat every renewal as time-critical.
What If My Application Is Denied?
Denials are usually about documentation — income proof, the Extra Help letter for low-income Medicare applicants, or incomplete FGFR/prescriber sections. Applications can be corrected and resubmitted, and we do it urgently. We review the denial letter, fix what triggered it, and resubmit on your behalf.
Take Control of Your Medication Costs
If you are struggling with the high cost of Balversa, our team may be able to help you access assistance programs designed to make brand specialty oral oncology therapy affordable. Check your eligibility today.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.